These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 10188888)

  • 21. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
    Makaiová I; Kausitz J; Hupka S; Michaliková B; Vivodová M; Bohunický L
    Czech Med; 1989; 12(1):34-9. PubMed ID: 2498049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
    Niikura N; Hashimoto J; Kazama T; Koizumi J; Ogiya R; Terao M; Oshitanai R; Morioka T; Tsuda B; Okamura T; Saito Y; Iwaisako K; Iwamoto T; Hayashi N; Imai Y; Tokuda Y
    Breast Cancer; 2016 Jul; 23(4):662-7. PubMed ID: 26037335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Mouridsen H; Dombernowsky P
    Eur J Cancer; 2004 Mar; 40(4):481-6. PubMed ID: 14962712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour marker CA15-3: possible uses in the routine management of breast cancer.
    Tomlinson IP; Whyman A; Barrett JA; Kremer JK
    Eur J Cancer; 1995 Jun; 31A(6):899-902. PubMed ID: 7646918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
    del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
    Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
    Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
    J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
    Mathew J; Prinsloo P; Agrawal A; Gutteridge E; Marenah C; Robertson JF; Cheung KL
    Breast; 2014 Oct; 23(5):567-72. PubMed ID: 24874285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer.
    Prior JO; Barghouth G; Delaloye JF; Leyvraz S; Bischof Delaloye A
    Nucl Med Commun; 2003 Jan; 24(1):29-36. PubMed ID: 12501017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
    O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
    Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study.
    Nicolini A; Carpi A; Michelassi C; Spinelli C; Conte M; Miccoli P; Fini M; Giardino R
    Biomed Pharmacother; 2003 Dec; 57(10):452-9. PubMed ID: 14637388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
    Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
    Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.